Want to see AU:IPD full AI Analyst Report?
IPD Stock Chart & Stats
AU$0.01
AU$0.00(0.00%)
At close: 4:00 PM EDT
AU$0.01
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.01 - AU$0.06
Previous CloseN/A
Volume44.23M
Average Volume (3M)853.05K
Market Cap
AU$21.97M
Enterprise ValueAU$71.86
Total Cash (Recent Filing)AU$18.85M
Total Debt (Recent Filing)AU$21.93M
Price to Earnings (P/E)―
Beta2.50
Next Earnings
Aug 27, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding3,662,493,700
10 Day Avg. Volume551,953
30 Day Avg. Volume853,052
Financial Highlights & Ratios
PEG Ratio-0.20
Price to Book (P/B)3.45
Price to Sales (P/S)5.55
P/FCF Ratio-4.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.01Price Target Upside33.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)AU$20.34M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsAn 86.25% gross margin indicates strong product-level economics and pricing power for its bioimpedance devices and consumables. High gross margins provide durable upside to operating leverage as revenue scales, supporting long-term profitability prospects if operating costs are controlled.
Consistent Revenue GrowthSustained revenue growth (~10% year) signals expanding clinical adoption of the company’s measurement technology. Persistent top-line momentum supports installed-base expansion, capacity utilization and the potential for recurring revenue from increasing patient testing volumes over the next several quarters.
Installed-base Recurring Revenue PotentialThe business model includes consumables and software tied to installed devices, creating recurring revenue streams. As the installed base grows, consumable and software usage can provide predictable, durable revenue and margin expansion independent of new capital-equipment sales.
Bears Say
Negative Operating And Free Cash FlowNegative operating and free cash flow with worsening FCF growth indicate the core business currently consumes cash. Over months this reduces financial flexibility, increases reliance on external funding, and constrains the company’s ability to invest in sales, R&D, or pursue profitable scale without addressing cash burn.
Negative Net And EBIT MarginsPersistent negative EBIT and net margins imply operating expenses outpace gross profit. Without structural cost control or meaningful scale gains, losses will continue, impairing ability to generate sustainable earnings and reducing headroom for reinvestment or dividend policy changes.
Negative Return On EquityNegative ROE shows the company is not generating returns on shareholder capital. Over time this can limit access to cheaper capital, weaken investor confidence, and pressure strategic choices unless profitability and cash generation improve to restore positive returns.
Impedimed Limited News
IPD FAQ
What was Impedimed Limited’s price range in the past 12 months?
Impedimed Limited lowest share price was AU$0.01 and its highest was AU$0.06 in the past 12 months.
What is Impedimed Limited’s market cap?
Impedimed Limited’s market cap is AU$21.97M.
When is Impedimed Limited’s upcoming earnings report date?
Impedimed Limited’s upcoming earnings report date is Aug 27, 2026 which is in 16 days.
How were Impedimed Limited’s earnings last quarter?
Impedimed Limited released its earnings results on Feb 20, 2026. The company reported -AU$0.006 earnings per share for the quarter, missing the consensus estimate of -AU$0.002 by -AU$0.004.
Is Impedimed Limited overvalued?
According to Wall Street analysts Impedimed Limited’s price is currently Undervalued.
Does Impedimed Limited pay dividends?
Impedimed Limited does not currently pay dividends.
What is Impedimed Limited’s EPS estimate?
Impedimed Limited’s EPS estimate is >-0.01.
How many shares outstanding does Impedimed Limited have?
Impedimed Limited has 3,662,493,700 shares outstanding.
What happened to Impedimed Limited’s price movement after its last earnings report?
Impedimed Limited reported an EPS of -AU$0.006 in its last earnings report, missing expectations of -AU$0.002. Following the earnings report the stock price went down -5.882%.
Which hedge fund is a major shareholder of Impedimed Limited?
Currently, no hedge funds are holding shares in AU:IPD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Impedimed Limited Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
AU$0.01 (33.33% Upside)
AU$0.01 (33.33% Upside)
Blogger Sentiment
Bullish
AU:IPD Sentiment 86%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$600.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-40.54%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
5.43%
Trailing 12-Months
Company Description
Impedimed Limited
Operating as a medical software technology provider, ImpediMed Limited is responsible for the development, production, and global sales of bioimpedance spectroscopy (BIS) instruments and accompanying software solutions, serving markets in Australia, North America, and internationally. Its product portfolio features SOZO, a non-invasive BIS device used for evaluating lymphedema and tracking fluid levels in heart failure patients. Additionally, it offers the SFB7, a single-channel, tetrapolar BIS instrument for analyzing body composition in healthy individuals, and ImpediVET, another single-channel, tetrapolar BIS device specifically designed for veterinary applications to measure fluid status and tissue composition. ImpediMed primarily sells its technology to hospitals and clinics. This Australian-headquartered firm, based in Pinkenba, was established in 1999.
IPD Stock 12 Month Forecast
Average Price Target
AU$0.01
▲(33.33% Upside)
Technical Analysis
Compumedics Limited
―
Uscom Limited
―
HeraMED Ltd.
―
Micro-X Ltd.
―
EMvision Medical Devices Ltd.
―